These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1098 related articles for article (PubMed ID: 7936862)
1. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection. Dennehy PH; Saracen CL; Peter G Pediatrics; 1994 Oct; 94(4 Pt 1):514-6. PubMed ID: 7936862 [TBL] [Abstract][Full Text] [Related]
2. The combination measles, mumps, rubella and varicella vaccine in healthy children. Arbeter AM; Baker L; Starr SE; Plotkin SA Dev Biol Stand; 1986; 65():89-93. PubMed ID: 3030864 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of a combined measles-mumps-rubella-chickenpox vaccine. Just M; Berger R; Just V Dev Biol Stand; 1986; 65():85-8. PubMed ID: 3030863 [TBL] [Abstract][Full Text] [Related]
4. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation. Pauksen K; Duraj V; Ljungman P; Sjölin J; Oberg G; Lönnerholm G; Fridell E; Smedmyr B; Simonsson B Bone Marrow Transplant; 1992 Jun; 9(6):427-32. PubMed ID: 1628126 [TBL] [Abstract][Full Text] [Related]
6. Combined vaccine against measles, mumps, rubella, and varicella. Brunell PA; Novelli VM; Lipton SV; Pollock B Pediatrics; 1988 Jun; 81(6):779-84. PubMed ID: 2835743 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Vesikari T; Baer M; Willems P Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879 [TBL] [Abstract][Full Text] [Related]
9. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996]. Zäch K; Nicoara C; Germann D; Matter L Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837 [TBL] [Abstract][Full Text] [Related]
10. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination. King GE; Markowitz LE; Heath J; Redd SC; Coleman S; Bellini WJ; Sievert A JAMA; 1996 Mar; 275(9):704-7. PubMed ID: 8594268 [TBL] [Abstract][Full Text] [Related]
11. Serologic response to measles-mumps-rubella vaccine among children with upper respiratory tract infection. Cilla G; Peña B; Marimón JM; Pérez-Trallero E Vaccine; 1996 Apr; 14(6):492-4. PubMed ID: 8782345 [TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children. Watson BM; Laufer DS; Kuter BJ; Staehle B; White CJ; Starr SE J Infect Dis; 1996 Mar; 173(3):731-4. PubMed ID: 8627041 [TBL] [Abstract][Full Text] [Related]
13. Measles and rubella antibody response after measles-mumps-rubella vaccination in children with afebrile upper respiratory tract infection. Ratnam S; West R; Gadag V J Pediatr; 1995 Sep; 127(3):432-4. PubMed ID: 7658276 [TBL] [Abstract][Full Text] [Related]
14. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination. Should we be concerned? Watada B; Kennedy K; Chan D; Church B; Patriquin M; Shariff F; Evans MF Can Fam Physician; 1998 Jan; 44():53-5. PubMed ID: 9481462 [No Abstract] [Full Text] [Related]
15. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. King SM; Saunders EF; Petric M; Gold R Bone Marrow Transplant; 1996 Apr; 17(4):633-6. PubMed ID: 8722367 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190 [TBL] [Abstract][Full Text] [Related]
17. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax. Reisinger KS; Brown ML; Xu J; Sullivan BJ; Marshall GS; Nauert B; Matson DO; Silas PE; Schödel F; Gress JO; Kuter BJ; Pediatrics; 2006 Feb; 117(2):265-72. PubMed ID: 16452343 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of a combined vaccine against measles-mumps-rubella produced on human diploid cells. Just M; Berger R; Glück R; Wegmann A Dev Biol Stand; 1986; 65():25-7. PubMed ID: 3549399 [TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age. Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM; Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of live attenuated varicella vaccine (Oka-RIT strain) and combined varicella and MMR vaccination in 13-17-month-old children. Vesikari T; Ohrling A; Baer M; Delem A; Bogaerts H; André FE Acta Paediatr Scand; 1991 Nov; 80(11):1051-7. PubMed ID: 1661057 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]